WANG Ting, WEN Hui, CUI Hua-qing, YIN Da-li. Research progress on indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorsJ. Acta Pharmaceutica Sinica, 2021,56(3): 723-733. doi: 10.16438/j.0513-4870.2020-1421
Citation: WANG Ting, WEN Hui, CUI Hua-qing, YIN Da-li. Research progress on indoleamine 2,3-dioxygenase 1 (IDO1) inhibitorsJ. Acta Pharmaceutica Sinica, 2021,56(3): 723-733. doi: 10.16438/j.0513-4870.2020-1421

Research progress on indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

  • Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme in the degradation of tryptophan to kynurenine. IDO1 is highly expressed in some tumor tissues. IDO1 can deplete tryptophan in tumor microenvironment, inhibit T cell function, and mediate the immune escape of tumor cells. Thus, IDO1 is considered a potential target of tumor immunotherapy. Currently, there are several IDO1 inhibitors in clinical research studies. The mechanism of IDO1-mediated tumor immune escape and the structure of IDO1 inhibitors are summarized in this review.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return